Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery

[1]  R. Benza,et al.  Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design , 2022, Respiratory research.

[2]  M. Quiñones-Mateu,et al.  Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices , 2022, International Journal of Pharmaceutics.

[3]  R. Scherließ,et al.  Formulation of rifampicin softpellets for high dose delivery to the lungs with a novel high dose dry powder inhaler. , 2022, International journal of pharmaceutics.

[4]  L. Harbaum,et al.  Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  A. Dolocan,et al.  Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations. , 2020, International journal of pharmaceutics.

[6]  C. Akdis,et al.  Environmental factors in epithelial barrier dysfunction. , 2020, The Journal of allergy and clinical immunology.

[7]  Duxin Sun.  Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit , 2020, The AAPS Journal.

[8]  Sang-Heon Cho,et al.  The effect of air pollutants on airway innate immune cells in patients with asthma , 2020, Allergy.

[9]  Bjarni V. Halldórsson,et al.  Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis , 2020, Nature Communications.

[10]  B. Nwaru,et al.  Changes in the prevalence of asthma and respiratory symptoms in western Sweden between 2008 and 2016 , 2019, Allergy.

[11]  Alan B. Watts,et al.  Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation. , 2019, Molecular pharmaceutics.

[12]  I. Annesi-Maesano,et al.  Latest news on relationship between thunderstorms and respiratory allergy, severe asthma, and deaths for asthma , 2019, Allergy.

[13]  Jong Sun Park,et al.  Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[14]  J. Luft,et al.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery , 2018, Pharmaceutical Research.

[15]  D. Na,et al.  Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals , 2018, Pharmaceutics.

[16]  C. Laurie,et al.  Genetic predisposition to obesity is associated with asthma in US Hispanics/Latinos: Results from the Hispanic Community Health Study/Study of Latinos , 2018, Allergy.

[17]  Sonal V. Bhujbal,et al.  Influence of excipients on physical and aerosolization stability of spray dried high‐dose powder formulations for inhalation , 2018, International journal of pharmaceutics.

[18]  Robert Walters,et al.  Drying technologies for biopharmaceutical applications: Recent developments and future direction , 2018 .

[19]  D. Caimmi,et al.  Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients , 2018, Open forum infectious diseases.

[20]  A. Sood,et al.  ERS/ATS workshop report on respiratory health effects of household air pollution , 2018, European Respiratory Journal.

[21]  Yotaro Takaku,et al.  Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis , 2018, ERJ Open Research.

[22]  Guilan Quan,et al.  Development of fine solid-crystal suspension with enhanced solubility, stability, and aerosolization performance for dry powder inhalation. , 2017, International journal of pharmaceutics.

[23]  A. Basit,et al.  A slippery slope: On the origin, role and physiology of mucus☆ , 2017, Advanced drug delivery reviews.

[24]  T. Gengenbach,et al.  Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation. , 2017, International journal of pharmaceutics.

[25]  Mark E. Anderson,et al.  Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma. , 2017, Molecular pharmaceutics.

[26]  A. Ogienko,et al.  Large porous particles for respiratory drug delivery. Glycine‐based formulations , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  P. Young,et al.  A review of co-milling techniques for the production of high dose dry powder inhaler formulation , 2017, Drug development and industrial pharmacy.

[28]  P. Young,et al.  Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance , 2017, Drug development and industrial pharmacy.

[29]  Peter J Dodd,et al.  The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling , 2016, PLoS medicine.

[30]  T. Gengenbach,et al.  How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder? , 2016, The AAPS Journal.

[31]  T. Gengenbach,et al.  L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  H. Collard,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old , 2016, European Respiratory Journal.

[33]  T. Okuda,et al.  Development of Spray-Freeze-Dried Powders for Inhalation with High Inhalation Performance and Antihygroscopic Property. , 2016, Chemical & pharmaceutical bulletin.

[34]  W. Britton,et al.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections , 2016, Pharmaceutical Research.

[35]  H. Chan,et al.  Powder Production and Particle Engineering for Dry Powder Inhaler Formulations. , 2015, Current pharmaceutical design.

[36]  N. Esfandiari.  Production of micro and nano particles of pharmaceutical by supercritical carbon dioxide , 2015 .

[37]  S. Lee,et al.  The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate , 2014, AAPS PharmSciTech.

[38]  M. Schatz,et al.  The allergic asthma phenotype. , 2014, The journal of allergy and clinical immunology. In practice.

[39]  K. Tsumoto,et al.  Next generation drying technologies for pharmaceutical applications. , 2014, Journal of pharmaceutical sciences.

[40]  M Hoppentocht,et al.  Technological and practical challenges of dry powder inhalers and formulations. , 2014, Advanced drug delivery reviews.

[41]  H. Hamishehkar,et al.  Alternative carriers in dry powder inhaler formulations. , 2014, Drug discovery today.

[42]  Xiaojiang Li,et al.  Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[43]  T. Gengenbach,et al.  Synergistic Antibiotic Combination Powders of Colistin and Rifampicin Provide High Aerosolization Efficiency and Moisture Protection , 2013, The AAPS Journal.

[44]  Jing Xu,et al.  Future of the particle replication in nonwetting templates (PRINT) technology. , 2013, Angewandte Chemie.

[45]  Waseem Kaialy,et al.  Treating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs. , 2013, International journal of pharmaceutics.

[46]  I. Larson,et al.  Effect of Surface Coating with Magnesium Stearate via Mechanical Dry Powder Coating Approach on the Aerosol Performance of Micronized Drug Powders from Dry Powder Inhalers , 2012, AAPS PharmSciTech.

[47]  P. Spagnolo,et al.  Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges , 2012, Multidisciplinary Respiratory Medicine.

[48]  Waseem Kaialy,et al.  Influence of lactose carrier particle size on the aerosol performance of budesonide from a dry powder inhaler , 2012 .

[49]  Ana Fernández Tena,et al.  Deposition of Inhaled Particles in the Lungs , 2012 .

[50]  L. Frumkin.  The Pharmacological Treatment of Pulmonary Arterial Hypertension , 2012, Pharmacological Reviews.

[51]  Ashish A. Pandya,et al.  Rendering protein-based particles transiently insoluble for therapeutic applications. , 2012, Journal of the American Chemical Society.

[52]  A. Baulard,et al.  Tuberculosis: the drug development pipeline at a glance. , 2012, European journal of medicinal chemistry.

[53]  K. Amighi,et al.  Lactose characteristics and the generation of the aerosol. , 2012, Advanced drug delivery reviews.

[54]  Waseem Kaialy,et al.  Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate. , 2012, International journal of pharmaceutics.

[55]  Stuart Williams,et al.  Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications , 2012, Journal of drug delivery.

[56]  A. Nokhodchi,et al.  Effect of carrier particle shape on dry powder inhaler performance. , 2011, International journal of pharmaceutics.

[57]  E. M. Littringer,et al.  The impact of spray drying outlet temperature on the particle morphology of mannitol , 2011 .

[58]  J. Heng,et al.  Role of Surface Chemistry and Energetics in High Shear Wet Granulation , 2011 .

[59]  A. Paudel,et al.  Influence of Solvent Composition on the Miscibility and Physical Stability of Naproxen/PVP K 25 Solid Dispersions Prepared by Cosolvent Spray-Drying , 2011, Pharmaceutical Research.

[60]  I. Larson,et al.  Use of surface energy distributions by inverse gas chromatography to understand mechanofusion processing and functionality of lactose coated with magnesium stearate. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[61]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[62]  Mabel Li Ling. Ng,et al.  Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. , 2011, International journal of pharmaceutics.

[63]  I. Larson,et al.  Determination of the polar and total surface energy distributions of particulates by inverse gas chromatography. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[64]  H. Smyth,et al.  Micronization of a Soft Material: Air-Jet and Micro-Ball Milling , 2010, AAPS PharmSciTech.

[65]  I. Larson,et al.  Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[66]  A. Hickey,et al.  Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dihydrate and D-mannitol carriers. , 2010, Journal of pharmaceutical sciences.

[67]  Xin Wang,et al.  Polyelectrolyte mediated formation of hydroxyapatite microspheres of controlled size and hierarchical structure. , 2009, Journal of colloid and interface science.

[68]  Raymond Lau,et al.  Effect of Particle Shape on Dry Particle Inhalation: Study of Flowability, Aerosolization, and Deposition Properties , 2009, AAPS PharmSciTech.

[69]  Rakesh Patel,et al.  Spray Drying Technology: an overview , 2009 .

[70]  D. Morton,et al.  The role of force control agents in high-dose dry powder inhaler formulations. , 2009, Journal of pharmaceutical sciences.

[71]  T. Pugsley,et al.  Flowability of moist pharmaceutical powders , 2009 .

[72]  Reinhard Vehring,et al.  Pharmaceutical Particle Engineering via Spray Drying , 2007, Pharmaceutical Research.

[73]  M. Raviglione,et al.  Tuberculosis and air travel: WHO guidance in the era of drug-resistant TB. , 2007, Travel medicine and infectious disease.

[74]  M. K. Bayliss,et al.  A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes , 2007, Drug Metabolism and Disposition.

[75]  Albert H. L. Chow,et al.  Particle Engineering for Pulmonary Drug Delivery , 2007, Pharmaceutical Research.

[76]  W. P. Oliveira,et al.  Spray drying conditions and encapsulating composition effects on formation and properties of sodium diclofenac microparticles , 2007 .

[77]  Simon Cawthorne,et al.  Particle engineering techniques for inhaled biopharmaceuticals. , 2006, Advanced drug delivery reviews.

[78]  N. Krug,et al.  Expression of Xenobiotic Metabolizing Enzymes in Different Lung Compartments of Smokers and Nonsmokers , 2006, Environmental health perspectives.

[79]  Chaoyang Wang,et al.  Combination of adsorption by porous CaCO3 microparticles and encapsulation by polyelectrolyte multilayer films for sustained drug delivery. , 2006, International journal of pharmaceutics.

[80]  C. Remuñán-López,et al.  Microencapsulated chitosan nanoparticles for lung protein delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[81]  J. Raper,et al.  Prediction of aerodynamic diameter of particles with rough surfaces , 2004 .

[82]  Jiaguo Yu,et al.  Morphological control of calcium oxalate particles in the presence of poly-(styrene-alt-maleic acid) , 2004 .

[83]  B. Shekunov,et al.  Optimisation of powders for pulmonary delivery using supercritical fluid technology. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[84]  Jiaguo Yu,et al.  Facile preparation of calcium carbonate particles with unusual morphologies by precipitation reaction , 2004 .

[85]  Joan May,et al.  Freeze-Drying/Lyophilization Of Pharmaceutical & Biological Products, Third Edition , 2004 .

[86]  J. Kuo,et al.  Preparation of DNA dry powder for non‐viral gene delivery by spray‐freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA , 2004, The Journal of pharmacy and pharmacology.

[87]  K. Griebenow,et al.  Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability. , 2002, Journal of pharmaceutical sciences.

[88]  J L Cleland,et al.  Encapsulation and stabilization of nerve growth factor into poly(lactic-co-glycolic) acid microspheres. , 2001, Journal of pharmaceutical sciences.

[89]  J. Carpenter,et al.  Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization. , 2001, Journal of pharmaceutical sciences.

[90]  P. Tiittanen,et al.  Ultrafine particles in urban air and respiratory health among adult asthmatics. , 2001, The European respiratory journal.

[91]  S J Prestrelski,et al.  Biopharmaceutical powders: particle formation and formulation considerations. , 2000, Current pharmaceutical biotechnology.

[92]  P. Giunchedi,et al.  Characterization of carbamazepine in systems containing a dissolution rate enhancer , 1995 .

[93]  C. Rhodes,et al.  The Effect of Process and Formulation Variables on the Properties of Spray‐dried β‐Galactosidase , 1994, The Journal of pharmacy and pharmacology.

[94]  G. Lim,et al.  Formation of microparticulate protein powder using a supercritical fluid antisolvent , 1993, Biotechnology and bioengineering.

[95]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[96]  J. Visser,et al.  Van der Waals and other cohesive forces affecting powder fluidization , 1989 .

[97]  Dean W. Matson,et al.  Rapid expansion of supercritical fluid solutions: solute formation of powders, thin films, and fibers , 1987 .

[98]  G. Amidon,et al.  Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. , 1983, Journal of pharmaceutical sciences.

[99]  N. Harnby,et al.  Moisture bonding in powders , 1978 .

[100]  K. Kendall,et al.  Surface energy and the contact of elastic solids , 1971, Proceedings of the Royal Society of London. A. Mathematical and Physical Sciences.

[101]  E. Weibel.  Morphometry of the Human Lung , 1965, Springer Berlin Heidelberg.

[102]  Xin Zhang,et al.  Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. , 2019, Drug discovery today.

[103]  F. Ahsan,et al.  Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[104]  D. Jarvis,et al.  The global burden of chronic respiratory disease in adults. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[105]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[106]  L. Gradon,et al.  Formation of particles for dry powder inhalers , 2014 .

[107]  G. Raskob,et al.  The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. , 2011, Chest.

[108]  D. Morton,et al.  The Influence of Force Control Agents on the Cohesive-Adhesive Balance in Dry Powder Inhaler Formulations , 2005 .

[109]  N. Di Lascio,et al.  Tissue distribution of drug-metabolizing enzymes in humans. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[110]  G. Zografi.  States of Water Associated with Solids , 1988 .

[111]  M. Woldenberg,et al.  Branching ratio and growth of tree-like structures. , 1986, Respiration physiology.